caffeine has been researched along with Psychoses in 24 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics." | 9.09 | CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. ( Afra, P; Albers, LJ; Collins, EJ; Kalow, W; Kennedy, JL; Ozdemir, V; Posner, P; Reist, C; Roy, R; Tang, BK; Walkes, W, 2001) |
| "Cigarette smoking and caffeine use are established and problematic drug-use behaviors in people with schizophrenia." | 7.75 | Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. ( Adolfo, AB; AhnAllen, CG; Tidey, JW, 2009) |
| "Psychosis-like perceptual distortions can occur in the general population, and both stress and caffeine can enhance the proneness to psychosis-like experiences, such as hallucinations." | 5.51 | Stress, caffeine and psychosis-like experiences-A double-blind, placebo-controlled experiment. ( Ágoston, C; Bernáth, L; Demetrovics, Z; Rogers, PJ, 2022) |
| "Individuals with schizophrenia use twice as much caffeine on average when compared to healthy controls." | 5.51 | Alteration of Resting Electroencephalography by Acute Caffeine Consumption in Early Phase Psychosis. ( Anderson, TJ; Fisher, DJ; McKearney, KJ; N Bissonnette, J; Tibbo, PG, 2022) |
| "Clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics." | 5.09 | CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. ( Afra, P; Albers, LJ; Collins, EJ; Kalow, W; Kennedy, JL; Ozdemir, V; Posner, P; Reist, C; Roy, R; Tang, BK; Walkes, W, 2001) |
| "Caffeine and nicotine are widely used by schizophrenia patients and may worsen psychosis and affect antipsychotic therapies." | 3.88 | Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. ( Avvisati, L; Buonaguro, EF; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Tomasetti, C, 2018) |
| "Cigarette smoking and caffeine use are established and problematic drug-use behaviors in people with schizophrenia." | 3.75 | Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. ( Adolfo, AB; AhnAllen, CG; Tidey, JW, 2009) |
| "Studies of substance use in first episode psychosis patients do not frequently assess non-pathological substance consumption among patients, but rather the prevalence of substance abuse or dependence disorders." | 1.43 | Differential effects of sex on substance use between first episode psychosis patients and healthy people. ( Baños, I; Barajas, A; Del Cacho, N; Dolz, M; Huerta-Ramos, E; Núñez, C; Ochoa, S; Sánchez, B; Usall, J, 2016) |
| " A marked (2 patients) or a moderate (2 patients) improvement of the clinical state of the patients occurred after the increase of CLO blood levels above the therapeutic threshold by the increase of CLO doses to very high values (ie, up to 1400 mg/d) or by the introduction of fluvoxamine, a potent CYP1A2 inhibitor, at low dosage (50 to 100 mg/d)." | 1.32 | Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. ( Allorge, D; Baumann, P; Bender, S; Broly, F; Cucchia, G; Eap, CB; Jaquenoud Sirot, E; Jonzier-Perey, M, 2004) |
| "Psychosis frequently occurs in Alzheimer's disease (AD), being associated with more severe cognitive decline, but the underlying mechanisms are unknown." | 1.32 | Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine. ( da Silva, AL; Dall'Igna, OP; Hoffmann, A; Lara, DR; Souza, DO, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (29.17) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 5 (20.83) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ágoston, C | 1 |
| Bernáth, L | 1 |
| Rogers, PJ | 1 |
| Demetrovics, Z | 1 |
| N Bissonnette, J | 2 |
| Anderson, TJ | 2 |
| McKearney, KJ | 2 |
| Tibbo, PG | 2 |
| Fisher, DJ | 2 |
| de Bartolomeis, A | 1 |
| Iasevoli, F | 1 |
| Marmo, F | 1 |
| Buonaguro, EF | 1 |
| Avvisati, L | 1 |
| Latte, G | 1 |
| Tomasetti, C | 1 |
| Peng, PJ | 1 |
| Chiang, KT | 1 |
| Liang, CS | 1 |
| Golden, LE | 1 |
| Sassoon, P | 1 |
| Cáceda, R | 1 |
| Núñez, C | 1 |
| Ochoa, S | 1 |
| Huerta-Ramos, E | 1 |
| Baños, I | 1 |
| Barajas, A | 1 |
| Dolz, M | 1 |
| Sánchez, B | 1 |
| Del Cacho, N | 1 |
| Usall, J | 1 |
| Adolfo, AB | 1 |
| AhnAllen, CG | 1 |
| Tidey, JW | 1 |
| BARUK, H | 1 |
| RACINE, M | 1 |
| Strydom, B | 1 |
| Bergh, JJ | 1 |
| Petzer, JP | 1 |
| Allorge, D | 2 |
| Chevalier, D | 1 |
| Lo-Guidice, JM | 1 |
| Cauffiez, C | 1 |
| Suard, F | 1 |
| Baumann, P | 2 |
| Eap, CB | 2 |
| Broly, F | 2 |
| TOCHTERMANN, W | 1 |
| BONETTI, U | 1 |
| STOLIAROV, GV | 1 |
| VOLODARSKAIA, LI | 1 |
| BUESSOW, H | 1 |
| de Leon, J | 2 |
| Bender, S | 1 |
| Jaquenoud Sirot, E | 1 |
| Cucchia, G | 1 |
| Jonzier-Perey, M | 1 |
| FAHRNI, R | 1 |
| Dall'Igna, OP | 1 |
| Hoffmann, A | 1 |
| da Silva, AL | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Caykoylu, A | 1 |
| Ekinci, O | 1 |
| Kuloglu, M | 1 |
| Adan, A | 1 |
| Odom-White, A | 1 |
| Ozdemir, V | 1 |
| Kalow, W | 1 |
| Posner, P | 1 |
| Collins, EJ | 1 |
| Kennedy, JL | 1 |
| Tang, BK | 1 |
| Albers, LJ | 1 |
| Reist, C | 1 |
| Roy, R | 1 |
| Walkes, W | 1 |
| Afra, P | 1 |
| De Freitas, B | 1 |
| Schwartz, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Caffeine on Cognition in Schizophrenia[NCT02832401] | 24 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for caffeine and Psychoses
| Article | Year |
|---|---|
Atypical antipsychotic dosing: the effect of smoking and caffeine.
Topics: Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Drug Adm | 2004 |
4 trials available for caffeine and Psychoses
| Article | Year |
|---|---|
Stress, caffeine and psychosis-like experiences-A double-blind, placebo-controlled experiment.
Topics: Caffeine; Double-Blind Method; Hallucinations; Humans; Psychotic Disorders; Surveys and Questionnair | 2022 |
Alteration of Resting Electroencephalography by Acute Caffeine Consumption in Early Phase Psychosis.
Topics: Caffeine; Electroencephalography; Humans; Psychotic Disorders; Rest; Schizophrenia | 2022 |
EEG Microstates in Early Phase Psychosis: The Effects of Acute Caffeine Consumption.
Topics: Brain; Brain Mapping; Caffeine; Electroencephalography; Humans; Psychotic Disorders | 2022 |
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Dose-Response Relat | 2001 |
19 other studies available for caffeine and Psychoses
| Article | Year |
|---|---|
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance.
Topics: Animals; Brain; Caffeine; Central Nervous System Agents; Cytoskeletal Proteins; Drug Interactions; D | 2018 |
Low-dose caffeine may exacerbate psychotic symptoms in people with schizophrenia.
Topics: Caffeine; Central Nervous System Stimulants; Humans; Male; Middle Aged; Psychotic Disorders; Schizop | 2014 |
A case report of late onset psychosis with dementia and aspirin and caffeine addiction.
Topics: Age of Onset; Aspirin; Caffeine; Central Nervous System Agents; Dementia; Diagnosis, Differential; H | 2015 |
Differential effects of sex on substance use between first episode psychosis patients and healthy people.
Topics: Adolescent; Adult; Alcohol Drinking; Caffeine; Cannabis; Comorbidity; Female; Humans; Illicit Drugs; | 2016 |
Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia.
Topics: Adult; Arousal; Beverages; Caffeine; Comorbidity; Cues; Female; Humans; Male; Middle Aged; Motivatio | 2009 |
Trial of circulatory treatment of early early dementia with folliculin and caffeine (physiological therapeutics or shock therapeutics?).
Topics: Caffeine; Estrogens; Mental Disorders; Psychotic Disorders; Schizophrenia | 1946 |
8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase.
Topics: Alkylation; Animals; Binding Sites; Caffeine; Halogens; Humans; Inhibitory Concentration 50; Kinetic | 2011 |
Identification of a novel splice-site mutation in the CYP1A2 gene.
Topics: Aged; Base Sequence; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Exons; Female; Humans; Introns; M | 2003 |
[Critical evaluation of the effect of various drugs in therapy of psychoneurological disorders].
Topics: Caffeine; Electroconvulsive Therapy; Humans; Psychosurgery; Psychotherapy; Psychotic Disorders | 1953 |
[Mental disorders caused by analgesic poisoning; description of a case caused by optalidon].
Topics: Aminopyrine; Analgesics; Barbiturates; Caffeine; Drug Combinations; Humans; Mental Disorders; Psycho | 1958 |
[On psychic disorders in caffeine poisoning].
Topics: Caffeine; Central Nervous System Agents; Humans; Medical Records; Mental Disorders; Psychoses, Subst | 1962 |
[ON THE PROBLEM OF PSYCHOSES DUE TO ANTIASTHMATIC DRUGS].
Topics: Anti-Asthmatic Agents; Antipyrine; Asthma; Atropine; Caffeine; Digitalis Glycosides; Ephedrine; Hall | 1964 |
Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.
Topics: Adult; Antipsychotic Agents; Caffeine; Chromatography, Gas; Clozapine; Cytochrome P-450 CYP1A2; DNA; | 2004 |
[Toxic psychoses due to sedormid, saridon and contra-pain].
Topics: Analgesics; Antipyrine; Caffeine; Drug Combinations; Humans; Hypnotics and Sedatives; Pain; Phenacet | 1950 |
Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine.
Topics: Adenosine; Adrenergic Agents; Alzheimer Disease; Amphetamine; Amyloid beta-Peptides; Animals; Avoida | 2004 |
Improvement from treatment-resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: a case report.
Topics: Bipolar Disorder; Caffeine; Central Nervous System Stimulants; Humans; Male; Middle Aged; Psychotic | 2008 |
Chronotype and personality factors in the daily consumption of alcohol and psychostimulants.
Topics: Adult; Alcohol Drinking; Caffeine; Circadian Rhythm; Female; Humans; Male; Nicotine; Personality; Pe | 1994 |
Clozapine levels and caffeine.
Topics: Adult; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A | 1996 |
Effects of caffeine in chronic psychiatric patients.
Topics: Adult; Bipolar Disorder; Caffeine; Chronic Disease; Humans; Male; Middle Aged; Neurocognitive Disord | 1979 |